Tetranectin and Paraoxonase 1 in Patients with Varying Stages of Heart Failure: A Cross-Sectional Analysis

<b>Background:</b> Heart failure (HF) is a leading cause of mortality across the globe, prompting ongoing research into novel biomarkers for improved risk stratification and patient management. <b>Methods:</b> This cross-sectional study aimed to investigate the relationship b...

Full description

Saved in:
Bibliographic Details
Main Authors: Paula Alexandra Vulciu, Luminita Pilat, Maria-Daniela Mot, Voicu Dascau, Calin Daniel Popa, Norberth-Istvan Varga, Maria Puschita
Format: Article
Language:English
Published: MDPI AG 2025-04-01
Series:Clinics and Practice
Subjects:
Online Access:https://www.mdpi.com/2039-7283/15/5/86
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850258017637892096
author Paula Alexandra Vulciu
Luminita Pilat
Maria-Daniela Mot
Voicu Dascau
Calin Daniel Popa
Norberth-Istvan Varga
Maria Puschita
author_facet Paula Alexandra Vulciu
Luminita Pilat
Maria-Daniela Mot
Voicu Dascau
Calin Daniel Popa
Norberth-Istvan Varga
Maria Puschita
author_sort Paula Alexandra Vulciu
collection DOAJ
description <b>Background:</b> Heart failure (HF) is a leading cause of mortality across the globe, prompting ongoing research into novel biomarkers for improved risk stratification and patient management. <b>Methods:</b> This cross-sectional study aimed to investigate the relationship between two promising biomarkers, tetranectin and paraoxonase 1, and the severity of heart failure in a cohort of 87 patients with cardiovascular risk factors. Participants were categorized into three groups based on their New York Heart Association (NYHA) classification: no HF (Control), NYHA class I (G1), and NYHA class II-IV (G2). <b>Results:</b> Our analysis revealed a stepwise decrease in both TETRA and PON1 levels with increasing HF severity, with the Control group exhibiting the highest levels and the G2 group the lowest. Interestingly, a significant positive correlation between TETRA and PON1 was observed only in the Control group, suggesting a potential interplay between these biomarkers in healthy individuals that may be disrupted with the onset of HF. Furthermore, both TETRA and PON1 were positively associated with left ventricular ejection fraction (LVEF) and negatively associated with diastolic dysfunction, indicating their potential involvement in both systolic and diastolic cardiac function. <b>Conclusions:</b> These findings suggest that TETRA and PON1 may serve as valuable biomarkers for assessing HF severity and prognosis. Further research is warranted to validate these findings in larger, prospective studies and to explore their clinical utility in guiding treatment decisions.
format Article
id doaj-art-632e49ea4daf454ba089a8c9deab9b77
institution OA Journals
issn 2039-7283
language English
publishDate 2025-04-01
publisher MDPI AG
record_format Article
series Clinics and Practice
spelling doaj-art-632e49ea4daf454ba089a8c9deab9b772025-08-20T01:56:16ZengMDPI AGClinics and Practice2039-72832025-04-011558610.3390/clinpract15050086Tetranectin and Paraoxonase 1 in Patients with Varying Stages of Heart Failure: A Cross-Sectional AnalysisPaula Alexandra Vulciu0Luminita Pilat1Maria-Daniela Mot2Voicu Dascau3Calin Daniel Popa4Norberth-Istvan Varga5Maria Puschita6Department of Biochemistry, “Vasile Goldis” Western University, B-dul Revolutiei Nr. 96, 310025 Arad, RomaniaDepartment of Biochemistry, “Vasile Goldis” Western University, B-dul Revolutiei Nr. 96, 310025 Arad, RomaniaDepartment of General Medicine, “Vasile Goldis” Western University, B-dul Revolutiei Nr. 96, 310025 Arad, RomaniaDepartment of Obstetrics and Gynecology, Medlife-Genesys Clinic, Dr. Cornel Radu Nr. 3, 310329 Arad, RomaniaSaint Luke of Crimeea Medical Center, B-dul Nicolae Titulescu Nr. 332, 310328 Arad, RomaniaDoctoral School, Department of General Medicine, “Victor Babes” University of Medicine and Pharmacy, Eftimie Murgu Square 2, 300041 Timisoara, RomaniaDepartment of Internal Medicine, “Vasile Goldis” Western University, B-dul Revolutiei Nr. 96, 310025 Arad, Romania<b>Background:</b> Heart failure (HF) is a leading cause of mortality across the globe, prompting ongoing research into novel biomarkers for improved risk stratification and patient management. <b>Methods:</b> This cross-sectional study aimed to investigate the relationship between two promising biomarkers, tetranectin and paraoxonase 1, and the severity of heart failure in a cohort of 87 patients with cardiovascular risk factors. Participants were categorized into three groups based on their New York Heart Association (NYHA) classification: no HF (Control), NYHA class I (G1), and NYHA class II-IV (G2). <b>Results:</b> Our analysis revealed a stepwise decrease in both TETRA and PON1 levels with increasing HF severity, with the Control group exhibiting the highest levels and the G2 group the lowest. Interestingly, a significant positive correlation between TETRA and PON1 was observed only in the Control group, suggesting a potential interplay between these biomarkers in healthy individuals that may be disrupted with the onset of HF. Furthermore, both TETRA and PON1 were positively associated with left ventricular ejection fraction (LVEF) and negatively associated with diastolic dysfunction, indicating their potential involvement in both systolic and diastolic cardiac function. <b>Conclusions:</b> These findings suggest that TETRA and PON1 may serve as valuable biomarkers for assessing HF severity and prognosis. Further research is warranted to validate these findings in larger, prospective studies and to explore their clinical utility in guiding treatment decisions.https://www.mdpi.com/2039-7283/15/5/86heart failuretetranectinparaoxonase 1heart failure biomarkersheart failure severityechocardiography
spellingShingle Paula Alexandra Vulciu
Luminita Pilat
Maria-Daniela Mot
Voicu Dascau
Calin Daniel Popa
Norberth-Istvan Varga
Maria Puschita
Tetranectin and Paraoxonase 1 in Patients with Varying Stages of Heart Failure: A Cross-Sectional Analysis
Clinics and Practice
heart failure
tetranectin
paraoxonase 1
heart failure biomarkers
heart failure severity
echocardiography
title Tetranectin and Paraoxonase 1 in Patients with Varying Stages of Heart Failure: A Cross-Sectional Analysis
title_full Tetranectin and Paraoxonase 1 in Patients with Varying Stages of Heart Failure: A Cross-Sectional Analysis
title_fullStr Tetranectin and Paraoxonase 1 in Patients with Varying Stages of Heart Failure: A Cross-Sectional Analysis
title_full_unstemmed Tetranectin and Paraoxonase 1 in Patients with Varying Stages of Heart Failure: A Cross-Sectional Analysis
title_short Tetranectin and Paraoxonase 1 in Patients with Varying Stages of Heart Failure: A Cross-Sectional Analysis
title_sort tetranectin and paraoxonase 1 in patients with varying stages of heart failure a cross sectional analysis
topic heart failure
tetranectin
paraoxonase 1
heart failure biomarkers
heart failure severity
echocardiography
url https://www.mdpi.com/2039-7283/15/5/86
work_keys_str_mv AT paulaalexandravulciu tetranectinandparaoxonase1inpatientswithvaryingstagesofheartfailureacrosssectionalanalysis
AT luminitapilat tetranectinandparaoxonase1inpatientswithvaryingstagesofheartfailureacrosssectionalanalysis
AT mariadanielamot tetranectinandparaoxonase1inpatientswithvaryingstagesofheartfailureacrosssectionalanalysis
AT voicudascau tetranectinandparaoxonase1inpatientswithvaryingstagesofheartfailureacrosssectionalanalysis
AT calindanielpopa tetranectinandparaoxonase1inpatientswithvaryingstagesofheartfailureacrosssectionalanalysis
AT norberthistvanvarga tetranectinandparaoxonase1inpatientswithvaryingstagesofheartfailureacrosssectionalanalysis
AT mariapuschita tetranectinandparaoxonase1inpatientswithvaryingstagesofheartfailureacrosssectionalanalysis